These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2292528)

  • 21. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.
    Höffler D; Koeppe P; Corcilius M; Przyklinik A
    Infection; 1990; 18(3):157-62. PubMed ID: 2365467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.
    Johnson CA; Ateshkadi A; Zimmerman SW; Hughes GS; Craig WA; Carey PM; Borin MT
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2650-5. PubMed ID: 8109931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Penetration of cefpodoxime into uterine and vaginal secretions from postpartum women after a single oral dose of cefpodoxime proxetil.
    Takasugi N; Tsunaga N; Sugino N; Numa F; Kato H
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1832-4. PubMed ID: 8843289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats.
    Liu P; Fuhrherr R; Webb AI; Obermann B; Derendorf H
    Eur J Pharm Sci; 2005; 25(4-5):439-44. PubMed ID: 15905079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. POPULATION PHARMACOKINETICS OF CEFPODOXIME IN BOTTLENOSE DOLPHINS (
    Linnehan BK; Lesman SP; Boucher JF; Grover GS; Brodie EC; Meegan JM; McClain AM; Ross KP; Jensen ED
    J Zoo Wildl Med; 2024 Sep; 55(3):611-619. PubMed ID: 39255202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bioavailability of cefpodoxime proxetil tablets relative to an oral solution.
    Borin MT; Forbes KK; Hughes GS
    Biopharm Drug Dispos; 1995 May; 16(4):295-302. PubMed ID: 7548778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of cefpodoxime proxetil with special reference to biochemical parameters, tissue residue, and spermatozoa motility in rats.
    Mujeeb MA; Pardeshi ML
    Indian J Med Sci; 2011 Feb; 65(2):43-9. PubMed ID: 23196312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.
    O'Neill P; Nye K; Douce G; Andrews J; Wise R
    Antimicrob Agents Chemother; 1990 Feb; 34(2):232-4. PubMed ID: 2327771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefpodoxime pharmacokinetics in children: effect of food.
    Kearns GL; Abdel-Rahman SM; Jacobs RF; Wells TG; Borin MT
    Pediatr Infect Dis J; 1998 Sep; 17(9):799-804. PubMed ID: 9779765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid pharmacokinetics of cefpodoxime proxetil in piglets.
    Abdel-Rahman SM; Maxson S; Teo C; Hubbard AE; Kearns GL
    J Clin Pharmacol; 2000 Mar; 40(3):290-5. PubMed ID: 10709158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human skin disposition of cefpodoxime after oral administration of its proxetil ester.
    Zolfino I; Senesi S; Campa M; Di Vito A; Mosca F; Favini P; Ducci M; Danesi R; Del Tacca M
    J Antimicrob Chemother; 1992 Nov; 30(5):731-3. PubMed ID: 1493994
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of timing of food on absorption of cefpodoxime proxetil.
    Borin MT; Driver MR; Forbes KK
    J Clin Pharmacol; 1995 May; 35(5):505-9. PubMed ID: 7657851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue.
    Naber KG; Kinzig M; Adam D; Sörgel F; Bajorski AH; Kiehn R
    Infection; 1991; 19(1):30-5. PubMed ID: 1707399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
    Stevens DL; Pien F; Drehobl M
    Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple dose pharmacokinetics of cefpodoxime in young adult and elderly patients.
    Backhouse C; Wade A; Williamson P; Tremblay D; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():29-34. PubMed ID: 2292527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia.
    Zuck P; Rio Y; Ichou F
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():71-7. PubMed ID: 2292534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.